UK's National Institute for Clinical Excellence (NICE) Recommends Roche's Herceptin For Stomach Cancer

Wall Street Journal -- LONDON (Dow Jones)--The U.K.'s National Institute for Health and Clinical Excellence Wednesday said it recommended Roche Holding AG's (ROG.VX) Herceptin oncology drug be made routinely available on the publicly funded National Health Service to certain patients with metastatic gastric cancer.

Back to news